Advertisement

Topics

Cerevance Company Profile

15:21 EDT 20th June 2019 | BioPortfolio

Cerevance is a recently formed pharmaceutical company focused on central nervous system diseases. The company’s strengths include a powerful technology platform, a pipeline of novel discovery-stage and clinical-stage compounds and a proven team. Its scientists believe that they are well positioned to deliver life-changing therapeutics for patients who have brain-related disorders.


News Articles [7 Associated News Articles listed on BioPortfolio]

Cerevance reports positive data from trial of Parkinson’s drug

Cerevance has reported positive data from a Phase I clinical trial of its first-in-class, orally-delivered compound in development, CVN424, for...Read More... The post Cerevance reports positive data ...

Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson's Disease Drug CVN424

Boston, MA – April 30, 2019 – Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has successfully completed its Phase 1 clinical trial of CVN...

Cerevance Appoints CNS Drug Developer James Summers, Ph.D. as Scientific Advisor

Dr. Summers to help guide Cerevance’s Drug Discovery and Development Efforts Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain d...

BioSpace Movers and Shakers: April 19

Biotech, pharma and life science companies make appointments to leadership roles, with additions at Cerevance, Obsidian, KSQ, Lygos, and more.

Cerevance Appoints Industry Veteran as Vice President of Drug Discovery

Former Head of Neuroscience Medicinal Chemistry at AstraZeneca, Roland Bürli, Ph.D., to lead therapeutic development against novel CNS targets Cerevance, a clinical-st...

Industry Central Nervous System Specialist Lee Dawson, Ph.D. Joins Cerevance as VP of Neuroscience

Dawson to help lead the pursuit of neuronal and glial targets revealed by cell-type-specific profiling of thousands of post-mortem human brain samples Cerevance, a clin...

Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424

Results Demonstrate Safety of CVN424 and Enable Initiation of Phase 2 Study in Patients Cerevance, a clinical stage biopharmaceutical company advancing new medicines fo...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Cerevance

Cerevance is a recently formed pharmaceutical company focused on central nervous system diseases. The company’s strengths include a powerful technology platform, a pipelin...

More Information about "Cerevance" on BioPortfolio

We have published hundreds of Cerevance news stories on BioPortfolio along with dozens of Cerevance Clinical Trials and PubMed Articles about Cerevance for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cerevance Companies in our database. You can also find out about relevant Cerevance Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record